Ipsen Stock Falls 2.5% and Drops Its Resistance Following Dysport News
The biopharmaceutical laboratory experiences a sharp decline in the morning, following a major clinical announcement about its botulinum toxin. The stock moves against the trend of a stable CAC 40 and loses contact with its technical resistance tested at the end of June.
A Decline that Dampens the Monthly Rebound Despite the Announcement on Dysport
Ipsen's stock falls 2.61% to €164.40, down from €168.80 the previous day. The stock is among the largest declines in the SBF 120, while the broader index remains nearly unchanged (+0.05%) and the CAC 40 hovers around equilibrium. This movement comes the day after the announcement of positive Phase III results for Dysport in the prevention of migraine, released on July 9, making Ipsen the first laboratory to demonstrate the efficacy of a botulinum toxin in both episodic and chronic forms. Thus, the day's decline appears to be a profit-taking after a positive streak marked by several external growth operations (Kartos Therapeutics at the end of June for $450 million, Memo Therapeutics at the beginning of July for €200 million). The performance over one month is just +4.1%, while the gain over one year reaches nearly 57%.
The Stock Remains Above Its Three Moving Averages, Resistance at €170.80
Despite today's drop, the price maintains a cushion above its trend references: it is 0.84% above the MM20 (€163.03) and 1.73% above the MM50 (€161.61), with the MM200 (€142.96) still significantly behind (+15%). The RSI at 59 indicates a still positive momentum but fading, consistent with the failure at the resistance of €170.80, tested at the beginning of the month. Should the decline continue, the next identified support is at €151.30. Regarding analysts' opinions, CIC Market Solutions reiterated its buy rating on July 9 with a target maintained at €175.00, representing a theoretical potential of about 6.4% at the current price. As a reminder, during the results publication for 2026 (May 28), the group highlighted clinical progress with IQIRVO, with 67% of patients responding, a file that remains central in the medium-term trajectory.
